IL-22 suppresses HSV-2 replication in human cervical epithelial cells.

Area of Science:

• Immunology
• Virology
• Cell Biology

Background:

• Interleukin-22 (IL-22) is implicated in antiviral immunity.
• The role of IL-22 in female reproductive tract (FRT) mucosal immunity against herpes simplex virus 2 (HSV-2) remains unclear.

Purpose of the Study:

• To investigate the potential inhibitory effect of IL-22 on HSV-2 infection in human cervical epithelial cells.
• To explore the underlying mechanisms of IL-22's action in the FRT.

Main Methods:

• Human cervical epithelial cells (End1/E6E7) were treated with IL-22.
• Expression of the IL-22 receptor complex (IL-22R1 and IL-10R2) was assessed.
• Levels of interferon-stimulated genes (ISGs) and tight junction proteins were measured.
• Activation of the JAK/STAT signaling pathway was analyzed via STAT1 and STAT3 phosphorylation.

Main Results:

• End1/E6E7 cells express the functional IL-22 receptor complex.
• IL-22 treatment upregulated ISGs (ISG15, ISG56, OAS-1, OAS-2, Mx2) and tight junction proteins (ZO-1, Occludin).
• IL-22 activated the JAK/STAT pathway through STAT1 and STAT3 phosphorylation.

Conclusions:

• IL-22 can inhibit HSV-2 infection in human cervical epithelial cells.
• IL-22 enhances FRT mucosal innate immunity against HSV-2.
• IL-22 shows potential as a therapeutic agent for HSV-2 in the FRT.